51
https://pubmed.ncbi.nlm.nih.gov/38116719
New proteomic technologies, such as proximity extension assays and DNA aptamers, combined with ion mobility spectrometry, show promise in addressing gaps in the discovery of diagnostic and prognostic biomarkers for ovarian cancer.
